Renal Carcinoma Clinical Trial
— COMPAR-KOfficial title:
Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney
The Urology Unit of AOUI Verona proposes a clinical study aimed at a preliminary evaluation of postoperative complications specifically focused on robotic partial nephrectomy (RAPN) procedures using three currently available platforms: - DaVinci®; - Hugo®; - Versius®. The questions it aims to answer are: Does the estimation of the post-operative complications suggest something? Are differences (intra- and post-operative, oncological, functional, technical, and economic) among the three intervention approaches observable? Participants will be invited to join one of these three experimental group: 1. surgery with the DaVinci platform; 2. surgery with the Hugo platform; 3. surgery with the Versius platform.
Status | Recruiting |
Enrollment | 45 |
Est. completion date | December 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - patient aged between 18 and 90 years old; - patient with localized kidney tumor suitable for partial nephrectomy; - patient able to understand and sign the informed consent; - patient compliance with the follow-up program. Exclusion Criteria: - patient who do not fall within the inclusion age range; - patient not suitable for partial nephrectomy; - patient unable to understand and sign the informed consent; - patient unable to follow the monitoring program; - patient refusal to participate to the study. |
Country | Name | City | State |
---|---|---|---|
Italy | Urology Unit, AOUI Verona | Verona | VR |
Lead Sponsor | Collaborator |
---|---|
Azienda Ospedaliera Universitaria Integrata Verona |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with postoperative complications | Overall postoperative complications (% score >0) are considered by Clavien-Dindo Classification 7 grades (I, II, IIIa, IIIb, IVa, IVb and V): the higher the grade, the higher the severity of the complication | Over the 4 days post surgery | |
Primary | Number of participants with moderate to major postoperative complications | Moderate to major complications (% score >=2) are considered by Clavien-Dindo Classification 7 grades (I, II, IIIa, IIIb, IVa, IVb and V): the higher the grade, the higher the severity of the complication | Over the 4 days post surgery | |
Primary | Number of participants with major postoperative complications | Major complications (% score >=3) are considered by Clavien-Dindo Classification 7 grades (I, II, IIIa, IIIb, IVa, IVb and V): the higher the grade, the higher the severity of the complication | Over the 4 days post surgery | |
Secondary | Overall duration of the surgery | Minutes | Intraoperative | |
Secondary | Number of intraoperative complications | Proportion of events | Intraoperative | |
Secondary | Type of intraoperative complications | Note of the event detail | Intraoperative | |
Secondary | Number of intraoperative technical malfunctions | Proportion of events | Intraoperative | |
Secondary | Type of intraoperative technical malfunctions | Note of the event detail | Intraoperative | |
Secondary | Estimated Blood Loss | Volume | Intraoperative | |
Secondary | Postoperative hospitalization | Days of recovery until the date of discharge | From the day after surgery up to 10 days postoperative | |
Secondary | Postoperative pain | Numerical Rating Scale (NRS) 0-10 scale for the self-reported rate of pain: zero meaning "no pain" and 10 meaning "the worst pain imaginable" | 1-4 days postoperative | |
Secondary | Positive Surgical Margins | Rate after histological examination | Up to 2 weeks postoperative (at the end of histological analysis) | |
Secondary | Serum Creatinine dosage for renal function assessment | Creatinine test | 1 month, 3 and 6 months follow-up | |
Secondary | Estimated Glomerular Filtration Rate for renal function assessment | eGFR calculation estimated by EPI-CKD formula | 1 month, 3 and 6 months follow-up | |
Secondary | Time taken for platform related timings | Configuration of the surgical table, Draping, Undraping, Docking, Undocking | From the room setting, through the overall surgical procedure, until postoperative room restoration for each of expected 45 surgeries (through study completion: about 4 months) | |
Secondary | Procedure-related costs | Estimate | From surgical procedure to the end of follow-up period (6 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04718584 -
the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
|
Phase 2 | |
Recruiting |
NCT03114826 -
Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients
|
N/A | |
Recruiting |
NCT02928692 -
Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium
|
Phase 3 | |
Recruiting |
NCT03475953 -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03638206 -
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT03786796 -
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
|
Phase 2 | |
Completed |
NCT03064308 -
The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery
|
N/A | |
Not yet recruiting |
NCT06318871 -
Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
|
Early Phase 1 | |
Not yet recruiting |
NCT05456074 -
Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)
|
||
Withdrawn |
NCT02370342 -
Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery
|
N/A | |
Recruiting |
NCT04773951 -
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
|
Phase 1 |